{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:16:35Z","timestamp":1789654595063,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974057"],"award-info":[{"award-number":["81974057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University, China","award":["JNU1AF-CFTP-2022-a01228"],"award-info":[{"award-number":["JNU1AF-CFTP-2022-a01228"]}]},{"name":"Science and Technology Plan Project of Guangzhou city","award":["202201020088"],"award-info":[{"award-number":["202201020088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disease caused by pathogenic variants of the gene <jats:italic>ABCB4<\/jats:italic>. This study aimed to investigate the <jats:italic>ABCB4<\/jats:italic> genotypic and the clinical phenotypic features of PFIC3 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The clinical and molecular genetic data of 13 new pediatric patients with PFIC3 as well as 82 reported ones in the PubMed and CNKI databases were collected and analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 13 new PFIC3 patients included six females and seven males, and the main presentations were hepatomegaly, splenomegaly, jaundice, and pruritus, as well as increased levels of gamma-glutamyl transpeptidase (GGT). Fourteen new <jats:italic>ABCB4<\/jats:italic> variants were detected, including eight diagnosed to be likely-pathogenic and six, pathogenic. Among all the 95 PFIC3 cases, hepatomegaly was observed in 85.3% (81\/95), pruritus in 67.4% (64\/95), splenomegaly in 52.6% (50\/95), jaundice in 48.4% (46\/95), portal hypertension in 34.7% (33\/95) and GGT elevation in 100% (88\/88) of the patients. Positive responses at varied degrees to oral ursodeoxycholic acid (UDCA) treatment were observed in 66.1% (39\/59) of the patients, among whom 38.5% (15\/39) fully recovered in terms of the laboratory changes. Although the condition remained stable in 53 patients (58.9%, 53\/90), the clinical outcomes were not promising in the rest 37 cases (41.1%, 37\/90), including 7 died, 27 having undergone while another 3 waiting for liver transplantation. A total of 96 <jats:italic>ABCB4<\/jats:italic> variants were detected in the 95 patients. PFIC3 patients with biallelic null variants exhibited earlier onset ages [10.5 (2, 18) vs. 19 (8, 60) months, p\u2009=\u20090.007], lower UDCA response rate [18.2% (2\/11) vs. 77.1% (37\/48), p\u2009=\u20090.001], and more unpromising clinical outcomes [80% (12\/15) vs. 33.3% (25\/75), p\u2009=\u20090.001], compared with those with non-biallelic null variants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PFIC3 presented with hepatomegaly, pruritus, splenomegaly and jaundice with increased serum GGT level as a biochemistry hallmark. Although varying degrees of improvement in response to UDCA therapy were observed, 41.1% of PFIC3 patients exhibited unfavorable prognosis. <jats:italic>ABCB4<\/jats:italic> genotypes of biallelic null variants were associated with severer PFIC3 phenotypes. Moreover, the 14 novel variants in this study expanded the <jats:italic>ABCB4<\/jats:italic> mutation spectrum, and provided novel molecular biomarkers for diagnosis of PFIC3 patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02597-y","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T10:02:59Z","timestamp":1671703379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical and genetic characterization of pediatric patients with progressive familial intrahepatic cholestasis type 3 (PFIC3): identification of 14 novel ABCB4 variants and review of the literatures"],"prefix":"10.1186","volume":"17","author":[{"given":"Rong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xian","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Zong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"2597_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-4-1","volume":"4","author":"A Davit-Spraul","year":"2009","unstructured":"Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"2597_CR2","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S2210-7401(12)70018-9","volume":"36","author":"E Jacquemin","year":"2012","unstructured":"Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S26\u201335.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"2597_CR3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/biomedicines10061238","volume":"10","author":"J Mart\u00ednez-Garc\u00eda","year":"2022","unstructured":"Mart\u00ednez-Garc\u00eda J, Molina A, Gonz\u00e1lez-Aseguinolaza G, Weber ND, Smerdou C. Gene therapy for acquired and genetic cholestasis. Biomedicines. 2022;10(6):1238.","journal-title":"Biomedicines"},{"issue":"1","key":"2597_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4254\/wjh.v14.i1.98","volume":"14","author":"S Alam","year":"2022","unstructured":"Alam S, Lal BB. Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3. Outcome and therapeutic strategies. World J Hepatol. 2022;14(1):98\u2013118.","journal-title":"World J Hepatol"},{"issue":"5","key":"2597_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.clinre.2014.03.001","volume":"38","author":"T Falgui\u00e8res","year":"2014","unstructured":"Falgui\u00e8res T, A\u00eft-Slimane T, Housset C, Maurice M. ABCB4. Insights from pathobiology into therapy. Clin Res Hepatol Gastroenterol. 2014;38(5):557\u201363.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"2597_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00424-006-0062-9","volume":"453","author":"RPJ Oude Elferink","year":"2007","unstructured":"Oude Elferink RPJ, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007;453(5):601\u201310.","journal-title":"Pflugers Arch"},{"issue":"4","key":"2597_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cld.2018.06.003","volume":"22","author":"LN Bull","year":"2018","unstructured":"Bull LN, Thompson RJ. Progressive familial intrahepatic cholestasis. Clin Liver Dis. 2018;22(4):657\u201369.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"2597_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146962","volume":"11","author":"Q Venot","year":"2016","unstructured":"Venot Q, Delaunay JL, Fouassier L, Delautier D, Falgui\u00e8res T, Housset C, et al. A PDZ-like motif in the biliary transporter ABCB4 interacts with the scaffold protein EBP50 and regulates ABCB4 cell surface expression. PLoS ONE. 2016;11(1): e0146962.","journal-title":"PLoS ONE"},{"issue":"1","key":"2597_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jceh.2013.10.005","volume":"4","author":"A Srivastava","year":"2014","unstructured":"Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014;4(1):25\u201336.","journal-title":"J Clin Exp Hepatol"},{"issue":"12","key":"2597_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/sj.ejhg.5201908","volume":"15","author":"D Degiorgio","year":"2007","unstructured":"Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet. 2007;15(12):1230\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"2597_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1053\/gast.2001.23984","volume":"120","author":"E Jacquemin","year":"2001","unstructured":"Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120(6):1448\u201358.","journal-title":"Gastroenterology"},{"issue":"2","key":"2597_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MPG.0b013e31824ef36f","volume":"55","author":"LJ Fang","year":"2012","unstructured":"Fang LJ, Wang XH, Knisely AS, Yu H, Lu Y, Liu LY, et al. Chinese children with chronic intrahepatic cholestasis and high \u03b3-glutamyl transpeptidase: clinical features and association with ABCB4 mutations. J Pediatr Gastroenterol Nutr. 2012;55(2):150\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2597_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cca.2018.07.035","volume":"486","author":"B Khabou","year":"2018","unstructured":"Khabou B, Mahjoub B, Barbu V, Balhoudi N, Wardani A, Sfar MT, et al. Phenotypic variability in Tunisian PFIC3 patients harboring a complex genotype with a differential clinical outcome of UDCA treatment. Clin Chim Acta. 2018;486:122\u20138.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2597_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/hep4.1149","volume":"2","author":"SB Schatz","year":"2018","unstructured":"Schatz SB, J\u00fcngst C, Keitel-Anselmo V, Kubitz R, Becker C, Gerner P, et al. Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset. Hepatol Commun. 2018;2(5):504\u201314.","journal-title":"Hepatol Commun"},{"key":"2597_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpeds.2021.04.040","volume":"236","author":"A Al-Hussaini","year":"2021","unstructured":"Al-Hussaini A, Lone K, Bashir MS, Alrashidi S, Fagih M, Alanazi A, et al. ATP8B1, ABCB11, and ABCB4 genes defects: novel mutations associated with cholestasis with different phenotypes and outcomes. J Pediatr. 2021;236:113-23.e2.","journal-title":"J Pediatr"},{"issue":"1","key":"2597_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1203\/00006450-200107000-00011","volume":"50","author":"HL Chen","year":"2001","unstructured":"Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, et al. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr Res. 2001;50(1):50\u20135.","journal-title":"Pediatr Res"},{"issue":"7","key":"2597_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.dld.2011.03.004","volume":"43","author":"I Giovannoni","year":"2011","unstructured":"Giovannoni I, Santorelli FM, Candusso M, Di Rocco M, Bellacchio E, Callea F, et al. Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. Dig Liver Dis. 2011;43(7):567\u201370.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2597_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1055\/s-0031-1273427","volume":"49","author":"R Kubitz","year":"2011","unstructured":"Kubitz R, Bode J, Erhardt A, Graf D, Kircheis G, M\u00fcller-St\u00f6ver I, et al. Cholestatic liver diseases from child to adult: the diversity of MDR3 disease. Z Gastroenterol. 2011;49(6):728\u201336.","journal-title":"Z Gastroenterol"},{"issue":"1","key":"2597_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.gene.2012.06.029","volume":"506","author":"T Dzagania","year":"2012","unstructured":"Dzagania T, Engelmann G, H\u00e4ussinger D, Schmitt L, Flechtenmacher C, Rtskhiladze I, et al. The histidine-loop is essential for transport activity of human MDR3. A novel mutation of MDR3 in a patient with progressive familial intrahepatic cholestasis type 3. Gene. 2012;506(1):141\u20135.","journal-title":"Gene"},{"issue":"7","key":"2597_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/0009922812451076","volume":"51","author":"R Ramraj","year":"2012","unstructured":"Ramraj R, Finegold MJ, Karpen SJ. Progressive familial intrahepatic cholestasis type 3: overlapping presentation with Wilson disease. Clin Pediatr (Phila). 2012;51(7):689\u201391.","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"2597_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/gutjnl-2014-306896","volume":"64","author":"R Gordo-Gilart","year":"2015","unstructured":"Gordo-Gilart R, Andueza S, Hierro L, Mart\u00ednez-Fern\u00e1ndez P, D\u2019Agostino D, Jara P, et al. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut. 2015;64(1):147\u201355.","journal-title":"Gut"},{"issue":"2","key":"2597_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3748\/wjg.v21.i2.699","volume":"21","author":"HZ Sun","year":"2015","unstructured":"Sun HZ, Shi H, Zhang SC, Shen XZ. Novel mutation in a Chinese patient with progressive familial intrahepatic cholestasis type 3. World J Gastroenterol. 2015;21(2):699\u2013703.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2597_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5223\/pghn.2015.18.3.202","volume":"18","author":"S Boga","year":"2015","unstructured":"Boga S, Jain D, Schilsky ML. Presentation of progressive familial intrahepatic cholestasis type 3 mimicking Wilson disease: molecular genetic diagnosis and response to treatment. Pediatr Gastroenterol Hepatol Nutr. 2015;18(3):202\u20138.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"5","key":"2597_CR24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.28300","volume":"63","author":"JL Delaunay","year":"2016","unstructured":"Delaunay JL, Durand-Schneider AM, Dossier C, Falgui\u00e8res T, Gautherot J, Davit-Spraul A, et al. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology. 2016;63(5):1620\u201331.","journal-title":"Hepatology"},{"issue":"5","key":"2597_CR25","first-page":"686","volume":"35","author":"M Deng","year":"2018","unstructured":"Deng M, Guo L, Song Y. clinical and genetic analysis of a family affected by progressive familial intraphepatic cholestasis type 3. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018;35(5):686\u201390.","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"issue":"7","key":"2597_CR26","first-page":"1601","volume":"36","author":"A Li","year":"2020","unstructured":"Li A, Dong Y, Xu Z, Wang F, Wang L, Yan J, et al. Progressive familial intrahepatic cholestasis type 3: a report of two cases in one pedigree. J Clin Hepatol. 2020;36(7):1601\u20134.","journal-title":"J Clin Hepatol"},{"key":"2597_CR27","first-page":"6292818","volume":"2020","author":"K Saleem","year":"2020","unstructured":"Saleem K, Cui Q, Zaib T, Zhu S, Qin Q, Wang Y, et al. Evaluation of a novel missense mutation in gene causing progressive familial intrahepatic cholestasis type 3. Dis Mark. 2020;2020:6292818.","journal-title":"Dis Mark"},{"issue":"6","key":"2597_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.5223\/pghn.2020.23.6.558","volume":"23","author":"W Zhang","year":"2020","unstructured":"Zhang W, Lin R, Lu Z, Sheng H, Xu Y, Li X, et al. Phenotypic and molecular characteristics of children with progressive familial intrahepatic cholestasis in South China. Pediatr Gastroenterol Hepatol Nutr. 2020;23(6):558\u201366.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"5","key":"2597_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.21037\/atm-20-3747","volume":"9","author":"J Bai","year":"2021","unstructured":"Bai J, Li L, Liu H, Liu S, Bai L, Ning H, et al. A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report. Ann Transl Med. 2021;9(5):426.","journal-title":"Ann Transl Med"},{"key":"2597_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100342","volume":"25","author":"P Lipi\u0144ski","year":"2021","unstructured":"Lipi\u0144ski P, Ciara E, Jurkiewicz D, P\u0142oski R, Wawrzynowicz-Syczewska M, Paw\u0142owska J, et al. Progressive familial intrahepatic cholestasis type 3: report of four clinical cases, novel ABCB4 variants and long-term follow-up. Ann Hepatol. 2021;25: 100342.","journal-title":"Ann Hepatol"},{"issue":"5","key":"2597_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1515\/jpem-2019-0314","volume":"33","author":"A K\u00fc\u00e7\u00fck\u00e7ongar Yava\u015f","year":"2020","unstructured":"K\u00fc\u00e7\u00fck\u00e7ongar Yava\u015f A, \u00c7avdarl\u0131 B, \u00dcnal Uzun \u00d6, Uncuo\u011flu A, G\u00fcnd\u00fcz M. A novel etiologic factor of highly elevated cholestanol levels: progressive familial intrahepatic cholestasis. J Pediatr Endocrinol Metab. 2020;33(5):665\u20139.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2597_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ejhg.2013.214","volume":"22","author":"D Degiorgio","year":"2014","unstructured":"Degiorgio D, Corsetto PA, Rizzo AM, Colombo C, Seia M, Costantino L, et al. Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction. Eur J Hum Genet. 2014;22(5):633\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2597_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.21591","volume":"46","author":"SY Morita","year":"2007","unstructured":"Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, et al. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology. 2007;46(1):188\u201399.","journal-title":"Hepatology"},{"key":"2597_CR34","doi-asserted-by":"publisher","first-page":"26872","DOI":"10.1038\/srep26872","volume":"6","author":"HJ Park","year":"2016","unstructured":"Park HJ, Kim TH, Kim SW, Noh SH, Cho KJ, Choi C, et al. Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3. Sci Rep. 2016;6:26872.","journal-title":"Sci Rep"},{"issue":"5","key":"2597_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"10","key":"2597_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1515\/hsz-2018-0441","volume":"400","author":"M Prescher","year":"2019","unstructured":"Prescher M, Kroll T, Schmitt L. ABCB4\/MDR3 in health and disease\u2013at the crossroads of biochemistry and medicine. Biol Chem. 2019;400(10):1245\u201359.","journal-title":"Biol Chem"},{"issue":"2","key":"2597_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/hep.28929","volume":"65","author":"JL Delaunay","year":"2017","unstructured":"Delaunay JL, Bruneau A, Hoffmann B, Durand-Schneider AM, Barbu V, Jacquemin E, et al. Functional defect of variants in the adenosine triphosphate\u2013binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). Hepatology. 2017;65(2):560\u201370.","journal-title":"Hepatology"},{"issue":"3","key":"2597_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jhep.2020.04.036","volume":"73","author":"AF St\u00e4ttermayer","year":"2020","unstructured":"St\u00e4ttermayer AF, Halilbasic E, Wrba F, Ferenci P, Trauner M. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol. 2020;73(3):651\u201363.","journal-title":"J Hepatol"},{"issue":"1","key":"2597_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0971-5916.178574","volume":"143","author":"A Lonardo","year":"2016","unstructured":"Lonardo A, Romagnoli D. Gamma glutamyl transferase: a novel cardiovascular outfit for an old liver test. Indian J Med Res. 2016;143(1):4\u20137.","journal-title":"Indian J Med Res"},{"issue":"1","key":"2597_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1089-3261(03)00136-3","volume":"8","author":"EU Sotil","year":"2004","unstructured":"Sotil EU, Jensen DM. Serum enzymes associated with cholestasis. Clin Liver Dis. 2004;8(1):41\u201354.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"2597_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/jmg.2004.026187","volume":"42","author":"SW van Mil","year":"2005","unstructured":"van Mil SW, Houwen RH, Klomp LW. Genetics of familial intrahepatic cholestasis syndromes. J Med Genet. 2005;42(6):449\u201363.","journal-title":"J Med Genet"},{"issue":"2","key":"2597_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/s-0030-1253223","volume":"30","author":"A Davit-Spraul","year":"2010","unstructured":"Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis. 2010;30(2):134\u201346.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"2597_CR43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3748\/wjg.v23.i5.763","volume":"23","author":"WL van der Woerd","year":"2017","unstructured":"van der Woerd WL, Houwen RH, van de Graaf SF. Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol. 2017;23(5):763\u201375.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2597_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-018-0475-8","volume":"25","author":"HL Chen","year":"2018","unstructured":"Chen HL, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J Biomed Sci. 2018;25(1):75.","journal-title":"J Biomed Sci"},{"issue":"7","key":"2597_CR45","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.dld.2019.04.013","volume":"51","author":"G Vitale","year":"2019","unstructured":"Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P. Familial intrahepatic cholestasis: new and wide perspectives. Dig Liver Dis. 2019;51(7):922\u201333.","journal-title":"Dig Liver Dis"},{"key":"2597_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/TCRM.S113052","volume":"13","author":"MA Jhaveri","year":"2017","unstructured":"Jhaveri MA, Kowdley KV. New developments in the treatment of primary biliary cholangitis\u2013role of obeticholic acid. Ther Clin Risk Manag. 2017;13:1053\u201360.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"2597_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.apsb.2014.12.011","volume":"5","author":"S Manley","year":"2015","unstructured":"Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015;5(2):158\u201367.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2597_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MPG.0b013e3181f50363","volume":"52","author":"C Colombo","year":"2011","unstructured":"Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr. 2011;52(1):73\u201383.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"2597_CR49","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/01.tp.0000282869.94152.4f","volume":"84","author":"C Englert","year":"2007","unstructured":"Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation. 2007;84(10):1361\u20133.","journal-title":"Transplantation"},{"issue":"6","key":"2597_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","volume":"74","author":"G Wei","year":"2021","unstructured":"Wei G, Cao J, Huang P, An P, Badlani D, Vaid KA, et al. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4 mouse model of PFIC3. J Hepatol. 2021;74(6):1416\u201328.","journal-title":"J Hepatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02597-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T11:40:25Z","timestamp":1671709225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02597-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02597-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the First Affiliated Hospital, Jinan University, and written informed consents were signed by the parents of all patients before this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}